Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis

Journal of the Neurological Sciences

Volumn 285, Issue 1-2, 2009, Pages 146-148

  Watanabe, Shohei ^a   Kimura, Takashi ^a   Suenaga, Koichi ^a   Wada, Sayoko ^a   Tsuda, Kenkichi ^a   Kasama, Shuhei ^a   Takaoka, Toshio ^a   Kajiyama, Koji ^a   Takeda, Masanaka ^a   Yoshikawa, Hiroo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Chloride; Diagnosis; Pathogenesis; Serum

Indexed keywords

CHLORIDE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CHLORIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PHENOTYPE; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS;

EID: 69549089902     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.06.026     Document Type: Article

References (20)

1. Rowland L.P., and Shneider N.A. Medical progress: amyotrophic lateral sclerosis. N Engl J Med 344 22 (2001) 1688-1700
2. Heath P.R., and Shaw P.J. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26 4 (2002) 438-458
3. Chen Q., Moulder K., Tenkova T., Hardy K., Olney J.W., and Romano C. Excitotoxic cell death dependent an inhibitory receptor activation. Exp Neurol 160 1 (1999) 215-225
4. Beck J., Lenart B., Kintner D.B., and Sun D. Na-K-Cl cotransporter contributes to glutamate-mediated excitotoxicity. J Neurosci 23 12 (2003) 5061-5068
5. Van Damme P., Callewaert G., Eggermont J., Robberecht W., and Van Den Bosch L. Chloride influx aggravates Ca2+-dependent AMPA receptor-mediated motoneuron death. J Neurosci 23 12 (2003) 4942-4950
6. De Koninck Y. Altered chloride homeostasis in neurological disorders: a new target. Curr Opin Pharmacol 7 1 (2007) 93-99
7. Kahle K.T., Staley K.J., Nahed B.V., Gamba G., Hebert S.C., Lifton R.P., et al. Roles of the cation-chloride cotransporters in neurological disease. Nat Clin Pract Neurol 4 9 (2008) 490-503
8. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 5 (2000) 293-299
9. Riviere M., Meininger V., Zeisser P., and Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55 4 (1998) 526-528
10. Ilzecka J., and Stelmasiak Z. Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 105 4 (2003) 237-240
11. Jaffe I.P. Tuberculous meningitis in childhood. Lancet. 1 8274 (1982) 738
12. Carunchio I., Mollinari C., Pieri M., Merlo D., and Zona C. GABA(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis. Eur J Neurosci 28 7 (2008) 1275-1285
13. Plum F., and Siesjo B.K. Recent advances in CSF physiology. Anesthesiology. 42 6 (1975) 708-730
14. Funk K., Woitecki A., Franjic-Wurtz C., Gensch T., Mohrlen F., and Frings S. Modulation of chloride homeostasis by inflammatory mediators in dorsal root ganglion neurons. Mol Pain 32 4 (2008)
15. Almer G., Teismann P., Stevic Z., Halaschek-Wiener J., Deecke L., Kostic V., et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 58 8 (2002) 1277-1279
16. Csenker E., Dioszeghy P., Fekete I., and Mechler F. Ion concentrations in serum and cerebrospinal fluid of patients with neuromuscular diseases. Arch Psychiatr Nervenkr 231 3 (1982) 251-258
17. Stambler N., Charatan M., Cedarbaum J.M., and Grp A.C.T.S. Prognostic indicators of survival in ALS. Neurology 50 1 (1998) 66-72
18. Qureshi M., Shui A., Dibernardo A.B., Brown Jr. R.H., Schoenfeld D.A., and Cudkowicz M.E. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9 6 (2008) 369-374
19. Traynor B.J., Zhang H., Shefner J.M., Schoenfeld D., Cudkowicz M.E., and Consortium N. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 63 10 (2004) 1933-1935
20. Caroscio J.T., Mulvihill M.N., Sterling R., and Abrams B. Amyotrophic lateral sclerosis. Its natural history. Neurol Clin 5 1 (1987) 1-8